New combo aims to beat drug resistance in blood cancer
NCT ID NCT03513562
First seen Feb 06, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This study tests whether adding venetoclax to ibrutinib can eliminate genetic mutations that make chronic lymphocytic leukemia (CLL) resistant to ibrutinib. About 28 adults with CLL who have developed these mutations while on ibrutinib will receive the combination for 12 cycles. The goal is to see if the mutations disappear and if patients achieve deep remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.